Corcept Therapeutics (Corcept Therapeutics) Market Cap : $2,367.5 Mil (As of Apr. 28, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Corcept Therapeutics's share price for the quarter that ended in Dec. 2023 was $32.48. Corcept Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 103.4 Mil. Therefore, Corcept Therapeutics's market cap for the quarter that ended in Dec. 2023 was $3,358.6 Mil.

Corcept Therapeutics's quarterly market cap increased from Jun. 2023 ($2,280.9 Mil) to Sep. 2023 ($2,806.1 Mil) and increased from Sep. 2023 ($2,806.1 Mil) to Dec. 2023 ($3,358.6 Mil).

Corcept Therapeutics's annual market cap increased from Dec. 2021 ($2,097.6 Mil) to Dec. 2022 ($2,190.1 Mil) and increased from Dec. 2022 ($2,190.1 Mil) to Dec. 2023 ($3,358.6 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Corcept Therapeutics's Enterprise Value for Today is $1,999.4 Mil.

Corcept Therapeutics Market Cap Historical Data

The historical data trend for Corcept Therapeutics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Market Cap Chart

Corcept Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Market Cap

Get a 7-Day Free Trial

1,386.04

3,053.79

2,097.61

2,190.13

3,358.59

Corcept Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Market Cap	Get a 7-Day Free Trial															2,190.13	2,342.66	2,280.89	2,806.13	3,358.59

Competitive Comparison of Corcept Therapeutics's Market Cap

For the Biotechnology subindustry, Corcept Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corcept Therapeutics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Market Cap distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Market Cap falls into.

Corcept Therapeutics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Corcept Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )	=	Share Price (A: Dec. 2023 )	*	Shares Outstanding (EOP) (A: Dec. 2023 )
	=	$32.48	*	103.405
	=	$3,358.6

Corcept Therapeutics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$32.48	*	103.405
	=	$3,358.6

Corcept Therapeutics (NAS:CORT) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Corcept Therapeutics Market Cap Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Corcept Therapeutics (Corcept Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

HTD:Germany

Address

149 Commonwealth Drive, Menlo Park, CA, USA, 94025

Website

https://www.corcept.com

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Executives

Swisher Daniel N Jr	director	C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer	officer: Chief Development Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb	officer: CHIEF FINANCIAL OFFICER	C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon	officer: Chief Accounting Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck	officer: See Remarks	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney	director	SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt	officer: Chief Scientific Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff	director, officer: CHIEF EXECUTIVE OFFICER	149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr	director, 10 percent owner	755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari	officer: Chief Financial Officer	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park	director	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer	officer: Chief Medical Officer	C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025